Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, T-Cell 6Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Non-Hodgkin 4Recurrence 3Lymphoma, Large B-Cell, Diffuse 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Prolymphocytic, T-Cell 2Leukemia 2Squamous Cell Carcinoma of Head and Neck 1Neoplasms, Plasma Cell 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Lymphoid 1Leukemia, Large Granular Lymphocytic 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Enteropathy-Associated T-Cell Lymphoma 1Burkitt Lymphoma 1

Interventions

fludarabine 6fludarabine phosphate 5Rituximab 5Cyclophosphamide 5Busulfan 4blinatumomab 3Lenalidomide 3thymoglobulin 2Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Methotrexate 2Melphalan 2Bone Marrow Transplantation 2Biopsy 2Bendamustine Hydrochloride 2Behavior Therapy 2Alemtuzumab 2venetoclax 1sargramostim 1romiplostim 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1lirilumab 1ibrutinib 1duvelisib 1copanlisib 1Vincristine 1Thiotepa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Lymphoid × duvelisib × Clear all
NCT05065866 2025-12-04

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
14 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡